Huntington's disease: SUCCESSFULLY TREATED FOR FIRST TIME

---

What is Huntington’s disease

• Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by a mutation in the huntingtin (HTT) gene. Specifically, normally there are ≤ 35 repeats of a CAG trinucleotide, but in HD people, there are more. The mutant protein (mHTT) becomes toxic, causing progressive damage to brain cells (especially in certain regions) and leads to worsening motor control, cognition, psychiatric symptoms, and ultimately death.
  

• There has so far been no cure. Treatments have largely been symptomatic, trying to control movements, mood, etc. There has been no proven way to meaningfully slow the underlying neurodegeneration in humans.

---

What is the new breakthrough

Recently (September 2025), researchers announced results from a gene therapy clinical trial that for the first time appears to slow the progression of Huntington’s disease significantly. 

Key points:

• The therapy is called AMT-130, developed by the biotech company uniQure, in collaboration with University College London (UCL). 

• It is delivered by direct brain surgery (neurosurgery) using a viral vector to carry therapeutic genetic material (microRNA-producing DNA) into neurons. The vector is designed to silence the mutant huntingtin gene, reducing production of the toxic protein. 

• The surgery is complex and long — about 12 to 20 hours. 

• In the trial, 29 patients were treated (17 with a high dose, 12 with a low dose) and followed over 36 months. 

• In patients given the high dose, disease progression (on a composite clinical scale, cUHDRS) was slowed by about 75% compared to external controls. 

• Also, functional decline measured by Total Functional Capacity (which gauges daily living abilities) was reduced by ~60% over the same period. 

• Some patients who were expected to become more disabled — e.g. require wheelchairs — retained functions; one medically retired patient was able to return to work. 

---

Why this is a big deal

• First disease-modifying therapy: This is the first time a treatment appears to alter the course of HD rather than only treating symptoms. A 75% slowing of progression is very large compared to anything before. 

• Single dose potential: Because the treatment is delivered once to the brain and the effects seem durable over the 3-year follow-up, there is hope this could be a one-time therapy.

• Hope for earlier treatment: If given earlier (before major damage), it may prevent or delay symptoms substantially. 

---

What remains to be resolved / limitations

While this is a huge advance, there are caveats, challenges, and unanswered questions:

1. Long-term durability & follow-up

   • The follow-up so far has been 3 years. It's promising, but whether the benefits continue beyond that (e.g. 5, 10 years) remains to be seen.

   • Also, whether new problems may emerge long term (safety, immune responses, etc.).

2. Surgical risk and complexity

   • Delivery requires highly specialized neurosurgery, with risks. The procedure is long (12-20 hours) and must accurately target deep brain regions. 

   • Not all patients may be candidates (due to health, brain anatomy, disease stage, etc.).

3. Cost and Accessibility

   • Gene therapies generally are expensive to develop and deliver. The cost will likely be very high. 

   • Regulatory approvals, manufacturing, training, infrastructure are needed; this could limit access, especially in less wealthy regions.

4. Stage of disease matters

   • The benefit might be larger if given early (before much neuronal death). Patients further along may have less capacity to recover.

   • Also, whether early, pre-symptomatic treatment is safe/effective remains to be proven.

5. External control vs randomized control

   • The trial used external controls (comparisons to matched patients not in the treatment) rather than a full randomized placebo group for all arms. External control comparisons can be less rigorous.

   • Peer review & full publication of data will be important to validate. 

6. Regulatory & Ethical Considerations

   • Approval will depend on regulatory authorities in each country. uniQure plans to apply for US license by early 2026. 

   • Ethical questions about genetic interventions, access, equity, etc.

---

What this could mean for patients

• Slower disease progression means more quality years: people might retain motor functions, independence, cognitive abilities for much longer.

• Reduction in disability: fewer people reaching severe stages as fast.

• Psychological hope: knowing there is a treatment that changes course gives hope to families and communities.

---

Big picture & comparison with past efforts

• There have been earlier therapies aiming to reduce huntingtin levels (e.g. antisense oligonucleotides, small molecules) but results have been mixed, and none have shown this level of slowing in human disease over years. 

• The approach of silencing or reducing mutant huntingtin has been a major research goal for decades. This result suggests that the strategy really can work in patients.

---

What to watch next

• Full peer-reviewed publication of the trial data: more detailed breakdowns (by age, stage, amount of CAG repeats, functional outcomes, side effects).

• Regulatory approval process in different countries.

• Long-term safety and efficacy data (beyond three years).

• Cost, manufacturing scale-up, and defining who will be eligible.

• Whether starting earlier (even before symptoms) is studied and shown to be effective.